In a phase 1b/2 trial of venetoclax combined with Rituximab or Obinutuzumab plus CHOP in previously untreated DLBCL, venetoclax combined with R-CHOP improved efficacy in BCL-2 positive DLBCL (including patients with double-expressor and double-hit DLBCL) compared to matched historical controls [100]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.